Traumatic Brain Injury Biomarkers Market By Biomarker Type (GFAP/UCH-L1 Protein Panel, Neurofilament Light Chain, Tau Biomarkers, S100B, MicroRNA Biomarkers, Extracellular Vesicle Biomarkers, Other Research Biomarkers); By Sample Type (Whole Blood, Plasma, Serum, Cerebrospinal Fluid, Saliva, Urine); By Testing Platform (Central Laboratory Immunoassays, Point-of-Care Cartridge Testing, Automated Immunoassay Systems, Research-Use Ultrasensitive Assay Platforms); By Application (Acute CT Triage, Diagnosis Support, Prognosis and Recovery Monitoring, Drug Discovery and Clinical Trials, Sports Concussion Research, Military and Blast Injury Assessment); By End User (Hospitals and Emergency Departments, Trauma Centers, Diagnostic Laboratories, Military Health Systems, Research Institutes and CROs, Sports Organizations); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Traumatic Brain Injury Biomarkers Market: Blood-Based CT Triage Moves Into Emergency Care

The Global Traumatic Brain Injury Biomarkers Market was valued at USD 1.17 billion in 2025 and is projected to reach USD 3.69 billion by 2032, growing at a CAGR of 17.83%, according to Strategic Market Research.

 

Clinical revenue in the Traumatic Brain Injury Biomarkers Market is primarily generated by assays that support clinician decisions on head CT use in adults with suspected mild traumatic brain injury. FDA-cleared tests measure glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), biomarkers associated with astroglial and neuronal injury. Results are interpreted alongside neurological assessment, injury history, and established imaging criteria. These assays do not independently diagnose concussion or confirm intracranial pathology.

 

The FDA classifies these products as Class II brain trauma assessment tests under product code QAT. Banyan’s Brain Trauma Indicator established the category through De Novo authorization in 2018. Abbott later secured four 510(k) clearances across i-STAT, Alinity i, and ARCHITECT, while bioMérieux received FDA clearance for VIDAS TBI in May 2024.

 

Emergency Departments Supply the Largest Eligible Patient Pool

The CDC recorded approximately 214,110 TBI-related hospitalizations in 2020 and 68,663 TBI-related deaths in 2023. A historical CDC surveillance estimate identified about 2.5 million TBI-related emergency-department visits in 2013, providing the closest broad public measure of patients entering an acute head-injury assessment pathway.

Emergency-department encounters cannot be treated as biomarker-testing volume. The total includes children, severe injuries, repeat visits, patients requiring immediate imaging and cases presenting outside the assay’s permitted testing window. Exact national data for adults meeting every FDA-label criterion are not publicly available.

Global Burden of Disease researchers estimated 20.84 million incident TBI cases, 37.93 million prevalent cases and 5.48 million years lived with disability worldwide in 2021. Global incidence includes patients who never reach a hospital, lack access to compatible testing equipment or fall outside the clinical population covered by current products.

Older adults represent a clinically significant hospital group. People aged 75 years and above account for approximately 32% of U.S. TBI-related hospitalizations and 28% of TBI-related deaths. Falls, anticoagulant use and age-related changes in biomarker concentrations complicate triage in this population. Suppliers seeking wider adoption will need stronger evidence for age-adjusted interpretation and high-risk elderly patients.

 

Negative Results Carry the Highest Economic Value

GFAP/UCH-L1 assays are designed primarily to rule out acute traumatic intracranial lesions visible on CT. A negative result can support CT avoidance when the patient meets product-label requirements and has no clinical feature requiring immediate imaging. An elevated result indicates that one or both biomarkers exceeded the assay threshold, but it does not prove that a CT-visible lesion is present.

The Banyan validation cohort reported 97.5% sensitivity, 36.5% specificity and 99.6% negative predictive value. VIDAS TBI reported 96.7% sensitivity, 41.2% specificity and 99.5% negative predictive value. Abbott’s whole-blood i-STAT study reported 96.5% sensitivity and 40.3% specificity.

High sensitivity supports the rule-out function. Specificity near 40% leaves many CT-negative patients with elevated results, limiting the assay’s ability to replace imaging across the entire suspected-TBI population.

Study positivity varied with patient selection and lesion prevalence. Elevated results occurred in 65.6% of evaluable participants in the Banyan cohort, 61.2% in the VIDAS cohort and 70.4% in Abbott’s whole-blood study. Abbott’s cohort had a CT-lesion prevalence of 29.2%, compared with approximately 6% in the Banyan and VIDAS populations.

Hospitals cannot apply these positivity rates to routine emergency-department volumes. Each study used different patient-selection criteria, specimen matrices, testing windows and lesion prevalence.

 

GFAP and UCH-L1 Control the Commercial Biomarker Mix

Strategic Market Research estimates that combined GFAP/UCH-L1 assays accounted for 69.4% of 2025 market revenue and will expand at a 13.1% CAGR through 2032.

Every FDA-cleared acute TBI blood test uses the GFAP/UCH-L1 combination, giving the panel a regulatory and procurement advantage over research-stage NfL, tau, microRNA and exosome assays. GFAP detects astroglial damage across a clinically useful acute window, while UCH-L1 rises quickly after neuronal injury.

Further revenue growth will depend on hospital implementation, reimbursement and guideline acceptance rather than additional validation of the two proteins alone.

 

Blood-Based Testing Leads Specimen Demand

Blood-based assays represented an estimated 76.8% share in 2025 and are projected to grow at a 13.6% CAGR through 2032.

Venous whole blood, plasma and serum fit emergency-care workflows more readily than cerebrospinal fluid, which requires an invasive lumbar puncture and has limited relevance in mild-TBI triage. Saliva may support future sports, military and field applications, but no saliva-based product has established a regulatory position comparable with cleared blood tests.

Cartridge-based whole-blood systems should increase the blood segment’s lead by eliminating centrifugation and shortening the interval between sample collection and imaging decisions.

 

Point-of-Care Cartridges Record the Fastest Platform Growth

Central-laboratory immunoassays held an estimated 61.3% share in 2025, supported by existing Alinity i, ARCHITECT and VIDAS installations. Point-of-care testing is forecast to grow at a faster 15.4% CAGR through 2032.

Abbott’s i-STAT whole-blood cartridge provides results in approximately 15 minutes and accepts samples collected within 24 hours of injury. VIDAS TBI provides an automated laboratory result in approximately 39 minutes for eligible patients presenting within 12 hours.

Emergency departments gain the greatest operational benefit when the result is available before a patient enters a prolonged observation or imaging queue. Hospitals with mature central laboratories may continue using automated systems, while trauma care centers prioritizing rapid disposition are more likely to adopt bedside cartridges.

 

CT Triage Generates Most Application Revenue

Acute CT-triage support accounted for an estimated 67.5% of market revenue in 2025 and is forecast to expand at a 12.9% CAGR through 2032.

CT triage has defined FDA indications, measurable imaging costs and a direct connection to emergency-department decisions. Prognosis, recovery tracking, sports concussion monitoring and military blast assessment remain research-heavy applications without standardized serial-testing protocols.

Longitudinal applications will generate wider clinical revenue only after studies establish reliable thresholds, testing intervals and evidence that repeated measurement changes patient management.

 

Hospitals Control Ordering, Imaging and Discharge

Hospitals, trauma centers and emergency departments represented an estimated 71.6% share in 2025 and are projected to grow at a 12.7% CAGR through 2032.

These facilities determine patient eligibility, collect samples, order CT scans and decide whether patients require observation, admission or discharge. Reference laboratories have less influence because off-site transport and delayed reporting reduce the value of acute triage.

Academic institutes, military research programs, contract research organizations and biopharmaceutical companies contribute demand for NfL, tau, microRNA and multianalyte research. Their spending primarily supports research-use reagents, testing services and biomarker-development programs rather than routine emergency testing.

 

North America Holds the Strongest Regulatory Position

North America captured an estimated 47.8% share in 2025 and is forecast to expand at a 12.0% CAGR through 2032.

The region benefits from the original FDA De Novo authorization, five subsequent 510(k) pathways, a large installed Abbott diagnostic base and a dedicated U.S. billing code. Hospital penetration remains uneven because FDA clearance does not guarantee guideline inclusion, payer coverage or local adoption.

Asia-Pacific is projected to record the fastest regional CAGR at 14.6%. Growth will concentrate in urban trauma centers, private hospital networks and military health systems with established immunoassay infrastructure. Limited reimbursement, inconsistent emergency protocols and weak access to confirmatory imaging will restrict adoption outside major cities.

Europe follows a more fragmented pathway. S100B remains part of selected Scandinavian protocols, while CE-marked GFAP/UCH-L1 assays provide an alternative for hospitals using VIDAS systems. National guidelines and reimbursement policies will continue to determine adoption country by country.

 

Whole-Blood Testing Removes a Major Processing Step

Abbott’s whole-blood i-STAT cartridge allows emergency departments to test EDTA whole blood without separating plasma. The cartridge measures GFAP and UCH-L1, reports individual concentrations and provides an overall elevated or non-elevated interpretation.

The 24-hour collection window gives clinicians more flexibility than the 12-hour window used by principal serum and plasma assays. Faster processing also improves suitability for community hospitals, military facilities and trauma centers where laboratory transport can delay imaging decisions.

One completed, interpretable GFAP/UCH-L1 panel is the most reliable commercial demand unit. Counting separate GFAP and UCH-L1 reagent packs would record two assays for one clinical decision on central-laboratory systems. Cartridge-only measurements would exclude serum and plasma testing.

 

Research Biomarkers Target Prognosis and Recovery

Neurofilament light chain remains elevated longer than many acute markers and is being studied for diffuse axonal injury, moderate-to-severe TBI and persistent neurological impairment. Total tau, phosphorylated tau and brain-derived tau are being evaluated in repetitive head trauma and secondary neurodegeneration.

Quanterix supports this research through ultrasensitive Simoa assays for GFAP, UCH-L1, NfL and tau. Academic and military programs use these platforms to measure concentrations that may fall below conventional immunoassay detection limits.

MicroRNAs may capture cell-death and inflammatory changes shortly after injury. Extracellular vesicles offer a method of isolating brain-derived molecular cargo from peripheral blood. APOE variants are being investigated as susceptibility markers for poor long-term outcomes rather than indicators of an acute injury event.

None of these formats has secured the regulated CT-triage position held by GFAP/UCH-L1 testing. Commercial uptake will require standardized thresholds, reproducible performance across platforms and prospective evidence linking results to clinical decisions.

The FDA has supported further investigation of blood GFAP and UCH-L1 as exploratory prognostic enrichment biomarkers for identifying patients at risk of persistent disability in mild-TBI clinical trials. The research designation does not create a routine prognostic or treatment-monitoring indication.

 

Adjacent Neurology Applications Improve Instrument Utilization

GFAP, NfL and tau are also studied or used in Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis, Parkinsonian disorders, stroke and hypoxic brain injury. Diagnostic manufacturers can use the same instrument base across several neurological research and testing programs.

Revenue from Alzheimer’s disease, multiple sclerosis or stroke assays should remain outside the TBI biomarker total. A shared analyte does not convert every test performed on the platform into traumatic brain injury revenue.

Current evidence also does not support routine GFAP, UCH-L1 or S100B testing for post-traumatic stress disorder. Military and trauma studies may use biomarker panels to distinguish neurological injury from psychiatric symptoms, but no recognized regulatory or guideline pathway supports biomarker-based PTSD diagnosis.

 

Guideline Adoption Trails Regulatory Clearance

The NICE NG232 head-injury guideline continues to base CT selection on clinical findings and established decision rules. NICE treats biomarker-based prediction of post-concussion outcomes and acute complications as a research area rather than a universal routine-care pathway.

S100B has a more established position in selected Scandinavian mild-head-injury protocols. Eligibility is limited to defined low-risk patients, and the pathway cannot be transferred directly to GFAP/UCH-L1 products because the biomarkers, thresholds and clinical criteria differ.

Emergency physicians in many countries continue to rely on the Canadian CT Head Rule, New Orleans Criteria, NEXUS II and local imaging protocols. Diagnostic suppliers must show that blood testing improves these workflows rather than adding another assessment step.

 

Abbott Leads Through Bedside and Laboratory Coverage

Abbott offers the broadest commercial portfolio through i-STAT plasma testing, i-STAT whole-blood testing and automated Alinity i and ARCHITECT assays. Hospitals can adopt Abbott testing at the bedside, near the patient or in a central laboratory without relying on one processing model.

The whole-blood cartridge provides Abbott with its clearest competitive advantage. A 15-minute result and the removal of plasma separation address emergency-department delays more directly than laboratory-only systems.

bioMérieux competes through VIDAS TBI, an automated serum assay available on VIDAS 3 and VIDAS KUBE analyzers. FDA clearance in 2024 added the United States to selected European, North African and South American markets where the CE-marked assay had already entered commercialization. Hospitals with installed VIDAS systems can add TBI testing without buying a dedicated instrument.

Banyan Biomarkers created the original FDA device category and supplied the clinical foundation for later GFAP/UCH-L1 products. Quanterix serves research and translational programs through ultrasensitive neurological assays. DiaSorin supplies S100 testing for selected regional and research applications.

Public disclosures do not provide company-level TBI revenue, completed tests or cartridge volumes. Manufacturer market shares therefore cannot be calculated reliably from regulatory clearances or installed instrument numbers alone.

 

Low Specificity Restricts Broad CT Replacement

Specificity near 40% sends many patients without CT-visible lesions to imaging after an elevated result. Hospitals gain most of the economic benefit from patients receiving a negative result rather than from precise identification of every lesion-positive case.

Age, renal function, extracranial injury, testing time, specimen matrix and analytical platform can alter measured concentrations. Serum, plasma and whole-blood cutoffs are product-specific and should not be treated as interchangeable.

High-risk patients generally proceed directly to CT, while very low-risk patients may be discharged using clinical criteria alone. Biomarker testing is most relevant for clinically uncertain adults who meet the product label, present within the permitted time window and do not already have a clear imaging decision.

 

Hospital Adoption Depends on Documented CT Avoidance

FDA clearance establishes assay performance for a defined population, but procurement decisions depend on changes in resource use. Hospitals will assess CT avoidance, emergency-department length of stay, radiology workload, patient transfers, repeat visits and missed-lesion rates.

GFAP/UCH-L1 panels used for acute CT triage account for most current clinical revenue. NfL, tau, microRNAs, extracellular vesicles and genetic susceptibility markers support longer-term development but remain dependent on indication-specific validation and regulatory approval.

 

Traumatic Brain Injury Biomarkers Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.17 Billion
Revenue Forecast in 2032	USD 3.69 Billion
Overall Growth Rate	CAGR of 17.83% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Biomarker Type, By Sample Type, By Testing Platform, By Application, By End User, By Geography
By Biomarker Type	GFAP/UCH-L1 Protein Panel, Neurofilament Light Chain, Tau Biomarkers, S100B, MicroRNA Biomarkers, Extracellular Vesicle Biomarkers, Other Research Biomarkers
By Sample Type	Whole Blood, Plasma, Serum, Cerebrospinal Fluid, Saliva, Urine
By Testing Platform	Central Laboratory Immunoassays, Point-of-Care Cartridge Testing, Automated Immunoassay Systems, Research-Use Ultrasensitive Assay Platforms
By Application	Acute CT Triage, Diagnosis Support, Prognosis and Recovery Monitoring, Drug Discovery and Clinical Trials, Sports Concussion Research, Military and Blast Injury Assessment
By End User	Hospitals and Emergency Departments, Trauma Centers, Diagnostic Laboratories, Military Health Systems, Research Institutes and CROs, Sports Organizations
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Market Drivers	Rising use of GFAP/UCH-L1 blood tests to support head CT decisions in suspected mild traumatic brain injury Growing adoption of rapid whole-blood point-of-care cartridges in emergency departments Increasing pressure to reduce avoidable CT scans, radiology workload, and emergency-department waiting times
Customization Option	Available upon request